EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[Á¦5ȸ ¼øõ¸¸ ³»½Ã°æ ¼¼¹Ì³ª (2017)]

½Ã°£: 2017³â 4¿ù 15ÀÏ (Åä) 19:00-22:00

Àå¼Ò: ¼øõ¿¡Äڱ׶óµå È£ÅÚ 4Ãþ ÄÁº¥¼Ç

±è¿øÁß ¼±»ý´Ô²²¼­ ¹ø¿ªÇÏ°í Á¦°¡ °¨¼öÇÑ Ã¥ÀÌ ¹æ±Ý ³ª¿Ô½À´Ï´Ù. Á¦°¡ ´ëÀå³»½Ã°æÀ» ¹è¿î ¹Ù·Î ±× Ã¥ÀÔ´Ï´Ù. ¼­Á¾¿Á ¼±»ý´Ô²²¼­ ÀÌ Ã¥À» ÇÁ·Î±×·¥ Ã¥ÀÚ¿¡ ¼Ò°³ÇØ ÁÖ¼Ì°í ¸î ±ÇÀ» ±¸ÀÔÇÏ¿© ¼¼¹Ì³ª Âü¼®ÀÚ ¸î ºÐ¿¡°Ô °æÇ°À¸·Î Á¦°øÇϼ̽À´Ï´Ù.^^ Á¦°¡ ¸¶Áö¸·¿¡ °¨¼öÀÇ ±ÛÀ» ½è´Âµ¥ ¾Æ·¡¿¡ ¼Ò°³ÇÕ´Ï´Ù.

'Cotton and William's ¼ÒÈ­±â ³»½Ã°æ °Ë»çÀÇ ½ÇÁ¦'°¡ ¿ì¸®¸»·Î ¹ø¿ªµÈ´Ù±â¿¡ Áñ°Å¿î ¸¶À½À¸·Î »ìÆ캸¾Ò´Ù. 1994³â ³»°ú Àü°øÀÇ 2³âÂ÷ °¡À» À§³»½Ã°æÀ» óÀ½ ¹è¿ï ¶§¿¡´Â ³»½Ã°æ ¼ú±â¿¡ ´ëÇÑ ÁÁÀº ±³Àç°¡ ¾ø¾î¼­ ÀûÁö ¾ÊÀº ¾î·Á¿òÀ» °Þ¾ú´Ù. ±×¶§±îÁö ¿ì¸®¸» ³»½Ã°æ Ã¥Àº ¹Î¿µÀÏ ±³¼ö´Ô²²¼­ 1993³â ³»³õÀº '»óºÎÀ§Àå°ü ³»½Ã°æÁø´Ü' ¹Û¿¡ ¾ø¾ú´Ù. Áúº´¿¡ ´ëÇÑ ¼³¸íÀº Àß µÇ¾î ÀÖ´Â ¹Ý¸é ³»½Ã°æ ¼ú±â ºÎºÐÀº ´Ù¼Ò ºÎÁ·ÇÏ¿© ÀûÀÝÀº ¸ñ¸¶¸§ÀÌ ÀÖ¾ú´Ù. 1996³â ´ëÀå³»½Ã°æÀ» óÀ½ ¹è¿ì´Â °úÁ¤¿¡¼­µµ ¸¶Âù°¡Áö¿´´Ù. ´ç½Ã ³»½Ã°æ ÃʽÉÀÚµéÀÌ ¼ú±â¸¦ ¹è¿ï ¼ö ÀÖ´Â ÃÖ»óÀÇ ±³°ú¼­°¡ 'Cotton and William's ¼ÒÈ­±â ³»½Ã°æ °Ë»çÀÇ ½ÇÁ¦'¿´´Ù. ȯÀÚÀÇ ÀÚ¼¼³ª ³»½Ã°æ Àâ´Â ¹ýºÎÅÍ ¾î·Á¿î °íºñ¸¦ ³Ñ¾î°¡´Â ¹ý, ¹®Á¦ ¹ß»ý ½Ã ´ëó¹ý µî ±×¾ß¸»·Î ¾ËÂ¥ Á¤º¸°¡ °¡µæ Âù Ã¥À̾ú´Ù. ÇØ´ç ºÎºÐÀ» º¹»çÇÏ¿© µé°í ´Ù´Ï¸é¼­ º¸°í ¶Ç º¸¾Ò´ø ±â¾ïÀÌ »õ·Ó´Ù. 3¹ø Á¤µ¶ÇÏ¿´´ø °Í °°´Ù. ÀÌdz·Ä ±³¼ö´ÔÀÇ Ãßõ¿¡ µû¶ó ³»½Ã°æÀ» óÀ½ ¹è¿ì±â Àü¿¡ 1¹ø, ³»½Ã°æ ½ÃÀÛ 1´Þ ÈÄ¿¡ 1¹ø, ¹Ý³â ÈÄ¿¡ 1¹ø, µµÇÕ 3¹øÀ» Àоú´Ù. óÀ½¿¡´Â ¹«½¼ ³»¿ëÀÎÁö ¾Ë±â ¾î·Á¿ü´ø ºÎºÐµµ Á÷Á¢ ³»½Ã°æÀ» °æÇèÇÑ ÈÄ¿¡ ´Ù½Ã Àо´Ï ÂüÀ¸·Î ¸¹Àº Àǹ̰¡ ´ã±ä ±ÛÀ̾úÀ½À» ±ú´Þ¾Ò´Ù. ±³¼ö°¡ µÈ ÀÌÈÄ Á¦ÀÚµéÀ» ÁöµµÇÏ´Â µ¥¿¡¼­µµ ´Ã ÀÌ Ã¥ÀÇ ¼³¸í°ú ±×¸²À» ÀÌ¿ëÇÏ¿´´Ù.

³»½Ã°æ¿¡ °üÇÑ Ã¥ÀÌ ³ÑÄ¡´Â ½Ã´ë°¡ µÇ¾ú´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ³»½Ã°æ Ã¥µéÀÌ µå¹® Áúȯ, ¾î·Á¿î ¼ú±â¸¦ »ó¼¼È÷ ±â¼úÇÏ°í ÀÖÀ» »ÓÀÌ´Ù. ½¬¿î µí Çϸ鼭µµ ½±Áö ¾ÊÀº ³»½Ã°æ ±âº» ¼ú±â¿¡ ´ëÇÑ »ó¼¼ÇÑ ±³°ú¼­´Â ã¾Æº¸±â ¾î·Æ´Ù. ÀÌ·± »óȲ¿¡¼­ 'Cotton and William's ¼ÒÈ­±â ³»½Ã°æ °Ë»çÀÇ ½ÇÁ¦'´Â ³»½Ã°æÀ» ¹è¿ì´Â ÀÇ»ç, °£È£»ç, ³»½Ã°æ½Ç ¿î¿µÀÚ ¸ðµÎ¿¡°Ô ÇʼöÀûÀÎ Á¤º¸¸¦ Á¦°øÇÏ´Â ¹ÙÀ̺í·Î¼­ÀÇ ÀÔÁö´Â ¿©ÀüÇÏ´Ù°í ¸»ÇÒ ¼ö ÀÖ´Ù. ÀÌÁ¦ ¿ì¸®¸»·Î ¹ø¿ªµÇ¾úÀ¸´Ï º¸´Ù ¸¹Àº ºÐµéÀÌ ÀÌ Ã¥À» ÅëÇÏ¿© ±âº»±â¸¦ ´ÙÁö°í ´õ¿í ¹ßÀüÇÏ´Â °è±â°¡ µÇ±â¸¦ ¹Ù¶õ´Ù. (2017. 3. 31. ÀÌÁØÇà)

Áö¿ª¹æ¼Û¿¡ ¼¼¹Ì³ª ³»¿ëÀÌ ¹ú½á ¼Ò°³µÇ¾ú½À´Ï´Ù.


1. À§¼±Á¾ (ÀÌÁØÇà)

2017³â 4¿ù 15ÀÏ ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª

PPT PDF 3.0M

* Âü°í: EndoTODAY À§¼±Á¾


[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. Áú¹®]

¿ÜºÎ½½¶óÀ̵å ÀçÆǵ¶ÀÇ Á߿伺À» °­Á¶Çϼ̴µ¥¿ä... À¯¸® ½½¶óÀ̵尡 ¾Æ´Ñ paraffin blockÀ» ¿äûÇÏ´Â °æ¿ì°¡ ÀÚÁÖ ÀÖ´ÂÁö¿ä.

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. ÀÌÁØÇà ´äº¯]

´ëºÎºÐ ¿ÜºÎ À¯¸® ½½¶óÀ̵å·Î ³¡³»°í ÀÖ½À´Ï´Ù. Paraffin blockÀº ¸²ÇÁÁ¾°ú °°Àº Ư¼öÇÑ °æ¿ì¿¡ ¿äûÇϱ⵵ ÇÕ´Ï´Ù¸¸ ¸Å¿ì µå¹® ÀÏÀÔ´Ï´Ù. Paraffin blockÀ» ÀÌ¿ëÇÑ Ãß°¡ °Ë»ç°¡ ÇÊ¿äÇÑ °æ¿ì´Â ´ëºÎºÐ º» º´¿ø ³»½Ã°æ Àç°Ë¿¡¼­ ¾òÀº Á¶Á÷À» ÀÌ¿ëÇÏ°í ÀÖ½À´Ï´Ù.

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. Áú¹®]

Ä¡·á Àü°ú Ä¡·á ÈÄ º´¸®Áø´ÜÀÇ Â÷ÀÌ¿¡ ´ëÇÏ¿© Àß ¼³¸íÇØ Á̴ּµ¥¿ä.... ±³¼ö´ÔÀº ¸ðµç ¼±Á¾À» ESD·Î Ä¡·áÇÏ°í °è½Ã´ÂÁö¿ä? Ȥ½Ã EMR-C¿Í °°Àº ÀüÅëÀûÀÎ ¹æ¹ýÀ¸·Î Ä¡·áÇÏ´Â °æ¿ì´Â ¾ø´ÂÁö ±Ã±ÝÇÕ´Ï´Ù.

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. ÀÌÁØÇà ´äº¯]

½Ã¼ú Àü Á¶Á÷°Ë»ç¿¡¼­ °íµµ ¼±Á¾À̾ú´ø °æ¿ì´Â Àû¾îµµ 1/3¿¡¼­ ½Ã¼ú ÈÄ ¾ÏÀ¸·Î Áø´ÜÀÌ ¹Ù²ò´Ï´Ù. µû¶ó¼­ ¿øÄ¢ÀûÀ¸·Î °íµµ ¼±Á¾Àº ¸ðµÎ ESD·Î Ä¡·áÇÏ°í ÀÖ½À´Ï´Ù. Àúµµ ¼±Á¾Àº less invasiveÇÑ Á¢±ÙÀÌ °¡´ÉÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù. ÀÛ°í, flatÇÏ°í paleÇÑ Àúµµ ¼±Á¾Àº ablationÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× ÀÌ¿Ü´Â ´ëºÎºÐ ÀýÁ¦¼úÀ» ¼±ÅÃÇÏ°í ÀÖ½À´Ï´Ù. ¹°·Ð ESD·Î Ä¡·áÇÏ´Â °æ¿ì°¡ ¸¹Áö¸¸ °æ¿ì¿¡ µû¶ó¼­´Â EMR-P, inject and cut°ú °°Àº º¸´Ù ÀüÅëÀûÀÎ ÀýÁ¦¼úÀ» »ç¿ëÇϱ⵵ ÇÕ´Ï´Ù.

ÀüüÀûÀ¸·Î 6.9% (141/2,041)°¡ down-grade µÇ°í 15.9% (324/2,041)°¡ up-grade µÇ¾ú½À´Ï´Ù. Diagnostic group classificationÀÌ ±×·¸°Ô ¹Ù²î¾ú´Ù´Â ÀǹÌÀÔ´Ï´Ù. (Lee JH. Surg Endosc 2016 / PDF)

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. Áú¹®]

¼±Á¾Àº Àúµµ¿Í °íµµ·Î ³ª´¹´Ï´Ù. ±×·±µ¥ °£È¤ Àúµµ, Áߵ (intermediate grade), °íµµ·Î ³ª´¶ º´¸® °á°úÁö¸¦ ¸¸³³´Ï´Ù. Áߵ (intermediate grade) ¼±Á¾Àº ¾î¶»°Ô Á¢±ÙÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï±î?

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. ÀÌÁØÇà ´äº¯]

º´¸® ÀÇ»çµéÀÇ Ç¥ÁØÈ­ ³ë·ÂÀÌ ºÎÁ·ÇÑ °ÍÀº Á¤¸» ½É°¢ÇÑ ¹®Á¦ÀÔ´Ï´Ù. Áߵ (intermediate grade) ¼±Á¾À¸·Î ÀÇ·ÚµÈ °æ¿ì ¿ÜºÎ ½½¶óÀ̵å ÀçÆǵ¶À» ÇÏ¸é ´ëºÎºÐ Àúµµ ¼±Á¾À¸·Î ³ª¿É´Ï´Ù. µû¶ó¼­ Àú´Â Áߵ ¼±Á¾Àº ÀÏ´Ü Àúµµ ¼±Á¾¿¡ ÁØÇÏ¿© Á¢±ÙÇÏ°í ÀÖ½À´Ï´Ù.

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. Áú¹®]

Ä¡·á Àü°ú Ä¡·á ÈÄ º´¸®Áø´Ü Â÷ÀÌÀÇ ¿øÀο¡ ´ëÇÏ¿© ¾î¶»°Ô »ý°¢ÇϽôÂÁö¿ä.

[2017-4-15 ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª. ÀÌÁØÇà ´äº¯]

¼±Á¾À̳ª ¾ÏÀ¸·Î ESD¸¦ ½ÃÇàÇÑ ÈÄ non-neoplastic pathology°¡ ³ª¿À¸é ¾à°£ ³­°¨ÇÕ´Ï´Ù. ±×·¯³ª µå¹® ÀÏÀº ¾Æ´Õ´Ï´Ù. 2015³â ¾ÆÁÖ´ë ³í¹®À» º¸¸é (Yang MJ. Endoscopy. 2015) Àúµµ ¼±Á¾ÀÇ °æ¿ì 6%, °íµµ ¼±Á¾À̳ª À§¾ÏÀÇ °æ¿ì 3%¿¡¼­ ESD ÈÄ non-neoplastic pathology°¡ ³ª¿À°í ÀÖ½À´Ï´Ù.

BiopsyLGDHGD or cancer
No neoplasia at ESD39 (5.5%)13 (2.7%)
Neoplasia at ESD664470

ÀÌ·¯ÇÑ ¿øÀÎÀº Å©°Ô ¼¼ °¡Áö·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. (1) ÀÛÀº Á¾¾çÀº Á¶Á÷°Ë»ç·Î Á¦°ÅµÇ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. (2) ÀýÁ¦¼ú ÈÄ Ç¥º»À» 2 mm °£°ÝÀ¸·Î Àß¶ó º´¸® specimenÀ» ¸¸µé±â ¶§¹®¿¡ 2 mm ÀÌÇÏÀÇ Á¾¾çÀº º´¸®ÇÐÀûÀ¸·Î ¹ß°ßÇÏÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù. (3) ³»½Ã°æ ÀýÁ¦ ´ç½Ã mislocalizationµµ °¡´ÉÇÕ´Ï´Ù.

ForcepÀ¸·Î ÀÛÀº Á¶Á÷À» ¾òÀº ¸çÄ¥ ÈÄ ³»½Ã°æÀ» ÇØ º¸¸é ÀÇ¿Ü·Î Å« ±Ë¾çÀÌ ¸¸µé¾îÁø °æ¿ì°¡ ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç·Î »ó´çÈ÷ Å« º´¼Ò°¡ Á¦°ÅµÇ´Â ¼ö ÀÖ°Ú´Ù´Â »ý°¢ÀÔ´Ï´Ù. Mislocalization (Àü¹® ¿ë¾î·Î 'Çê¹ßÁú'À̶ó°í ÇÕ´Ï´Ù^^)Àº ¸Å¿ì µå¹® °Í °°½À´Ï´Ù.

* Âü°í: EndoTODAY Nonneoplastic pathology after ESD


2. ³»½Ã°æÀ» ÅëÇÑ ±â»ýÃæ Áúȯ (´Ü±¹´ëÇб³ ¼­¹Î)

Á¶Ãæ Áß Taenia¿Í ±¤Àý¿­µÎÁ¶ÃæÀÇ ±¸ºÐ¿¡ ´ëÇÏ¿© »ó¼¼È÷ ¼³¸íÇØ Áּ̽À´Ï´Ù.

Á¶ÃæÀÇ ÆíÀý
µÎ Á¾·ù°¡ ÀÖ´Ù. Taenia sp.ÀÇ ÆíÀý vs ±¤Àý¿­µÎÁ¶ÃæÀÇ ÆíÀý
Taenia´Â (1) ³¡ ºÎºÐ¸¸ µûÁö¸é °¡·Îº¸´Ù ¼¼·Î°¡ ±æ°í (2) ÆíÀýÀÌ Çϳª¾¿ ¶³¾îÁ® ³ª¿À´Â °æ¿ì°¡ ¸¹´Ù.
±¤Àý¿­µÎÁ¶ÃæÀº (1) °¡·Î°¡ ´õ ±æ°í (2) ¸î½Ê¼¾Æ¼ Âë µÇ´Â °æ¿ì°¡ ¸¹´Ù.

ÃÖ±Ù ºÐÀÚ»ý¹°ÇÐÀû ¿¬±¸¿¡ ÀÇÇÏ¸é ¿ì¸®³ª¶óÀÇ Anisakis´Â Anisakis simplex°¡ ¾Æ´Ï°í Anisakis pegreffiiÀÎ °æ¿ì°¡ ¸¹½À´Ï´Ù. (Molecular diagnosis of cause of anisakiasis in humans, South Korea. Hyemi Lim et al.)

¼­¹Î ±³¼ö´ÔÀº Ã¥ÀÚ¸¦ ÅëÇÏ¿© ÇØ»ê ¾î·ùÀÇ ¾Æ´Ï»çÅ°½º ¾ç¼º·ü¿¡ ´ëÇÑ Èï¹Ì·Î¿î ÀڷḦ ¼Ò°³ÇØ Áּ̽À´Ï´Ù.

* Âü°í: EndoTODAY ±â»ýÃæÇÐ


[2017-4-15. ÁÂÀå´Ô Áú¹®]

°ú°Åº¸´Ù ´ëº¯ Ãæ¶õ ¾ç¼º·üÀÌ ³·¾ÆÁ³½À´Ï´Ù. Çö ½ÃÁ¡¿¡¼­µµ º½°¡À»¿¡ Á¤±âÀûÀ¸·Î Àü °¡Á·ÀÌ ±â»ýÃæ¾àÀ» ¸ÔÀ» ÇÊ¿ä°¡ ÀÖ´Ù°í »ý°¢ÇϽʴϱî?

[2017-4-15. ¼­¹Î ±³¼ö´Ô ´äº¯]

º¹¿ëÇÒ ÇÊ¿ä°¡ ¾ø½À´Ï´Ù. ÇöÀç´Â 2-3% Á¤µµÀÌ°í ±×³ª¸¶ ´ëºÎºÐ µð½ºÅ丶ÀÔ´Ï´Ù. µð½ºÅ丶´Â ȸÃæ¾à¿¡ µèÁöµµ ¾Ê½À´Ï´Ù. °¡Á·ÀÇ ´ÜÇÕÀ» À§ÇÏ¿© ¸Ô´Â Á¤µµ´Â °¡´ÉÇÒ °Í °°½À´Ï´Ù.

[2017-4-15. ÁÂÀå´Ô Áú¹®]

¼Ò °£À» ³¯·Î ¸Ô¾úÀ» ¶§ °É¸± ¼ö ÀÖ´Â °³È¸Ãæ¿¡ ´ëÇÑ comment¸¦ ºÎŹÇÕ´Ï´Ù.

[2017-4-15. ¼­¹Î ±³¼ö´Ô ´äº¯]

ÃÖ±Ù ¿ì¸®³ª¶ó´Â ¼¼°èÀûÀ¸·Î °³È¸Ãæ °¨¿°ÀÌ ¸¹Àº ³ª¶ó°¡ µÇ¾ú½À´Ï´Ù. À¯±â°ßÀÌ ¹®Á¦ÀÔ´Ï´Ù. À¯±â°ßÀÌ ¿©±â Àú±â º¯À» º¸°í ´Ù´Ï¸é ±×¿¡ ÀÇÇÏ¿© ¼Ò°¡ °¨¿°µÇ´Â °Í ¾Æ´Ñ°¡ »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. ¸ö»ìÀ» ÀÏÀ¸Å°°í È£ÀüµÇ´Â °æ¿ìµµ ÀÖÁö¸¸ µå¹°°Ô Uveitis¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ÇÑ ¾È°úÀÇ ¿¬±¸¿¡ ÀÇÇϸé uveitis ȯÀÚÀÇ 1/4¿¡¼­ Ç×ü ¾ç¼ºÀ̶ó°í ÇÕ´Ï´Ù.


3. Formalin application for the treatment of radiation-induced hemorrhagic gastritis (¼øõ ¼º °¡·Ñ·Î º´¿ø ±èÈ£µ¿)

APC¸¦ ¿©·¯¹ø Çߴµ¥µµ ÃâÇ÷ÀÌ Áö¼ÓµÇ¾ú´ø ȯÀÚ¿¡¼­ formalin applicationÀ» 3¹ø ½ÃÇàÇÑ ÈÄ È£ÀüµÈ Áõ·Ê¸¦ ¼Ò°³ÇØ Áּ̽À´Ï´Ù. Formalin applicationÀ» Çϸé ȯÀÚ°¡ ½ÉÇÑ ÅëÁõÀ» ´À³¢±â ¶§¹®¿¡ deep sedationÀÌ ÇÊ¿äÇÏ´Ù°í ÇÕ´Ï´Ù.

* Âü°í: EndoTODAY ¹æ»ç¼± °ü·Ã À§Àå°ü ¼Õ»ó


4. Localized gastric amyloidosis with kappa, lamda coexpression (¼øõÇ÷¯½º³»°ú ¾È¿ëȯ)


Àü½Å ħ¹üÀÌ ¾øÀÌ ÇѵΠÀå±â¿¡ ±¹ÇÑµÈ localized formÀÇ amyloidosis¸¦ µå¹°°Ô °æÇèÇÏ°í ÀÖ½À´Ï´Ù. ´ëºÎºÐ ¿¹ÈÄ´Â ÁÁ´Ù°í »ý°¢µË´Ï´Ù. °ü·Ã ¹®ÇåÀ» ¼Ò°³ÇÕ´Ï´Ù.

Localized deposition of amyloid may occur in individual organs, in the absence of systemic involvement. The reason for localized deposition is unknown, but it is hypothesized that deposits result from local synthesis of amyloid protein, rather than the deposition of light chains produced elsewhere. We identified 20 cases of localized amyloidosis at our institution between 1993 and 2003. There were 11 males and nine females in the group. The mean age at the time of diagnosis was 65.5 years. Organs involved included skin, soft tissues, oropharynx, larynx, lung, bladder, colon, conjunctiva, and lymph node. In six of nine patients typed, the amyloid light chain was lambda. In those patients where follow-up was available (mean 7.6 years), none developed systemic disease. Localized amyloidosis occurs in a variety of organ systems. Evolution into systemic amyloidosis was not seen in our series of patients, supporting the hypothesis of local production of amyloid protein in these cases. (Biewend ML. Amyloid 2006)

* Âü°í 1: EndoTODAY À§ ¾Æ¹Ð·ÎÀ̵åÁõ

* Âü°í 2: EndoTODAY ´ëÀå ¾Æ¹Ð·ÎÀ̵åÁõ


5. À§»ý°Ë¿¡¼­ Ç︮ÄÚ¹ÚÅÍ ¾ç¼º·ü (À§¾ØÀå ¼­³»°ú ¼­Á¾¿Á)

[ÀÌÁØÇà commet]

Ç︮ÄÚ¹ÚÅÍ À½¼º À§¾ÏÀº ¸Å¿ì µå¹°´Ù°í ÇÕ´Ï´Ù. Çö °¨¿°Àº 70-80% ¼±ÀÌÁö¸¸ serology±îÁö °Ë»çÇϸé Ç︮ÄÚ¹ÚÅÍ À½¼º À§¾ÏÀº 1-2% ÀüÈÄÀÏ °Í °°½À´Ï´Ù.

Àü¹®°¡µé »çÀÌ¿¡¼­´Â ÀϺ»Ã³·³ ¿ì¸®µµ À§¾Ï ¿¹¹æÀ» À§ÇÑ Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á°¡ ÇÊ¿äÇÏ´Ù´Â ³íÀÇ°¡ È°¹ßÇÕ´Ï´Ù. °ü·Ã ÇÐȸ¿¡¼­µµ Á¦±ÕÄ¡·áÀÇ ÀûÀÀÁõÀ» ³ÐÈ÷±â À§ÇÏ¿© ³ë·ÂÇÏ°í ÀÖ½À´Ï´Ù. ÇöÀç ¿ì¸®³ª¶ó¿¡¼­´Â off label Ä¡·á°¡ ÀÎÁ¤µÇÁö ¾Ê°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á¿¡ ´ëÇؼ­´Â ¾î´À Á¤µµ ´À½¼ÇÑ ±âÁØÀÌ Àû¿ëµÇ°í ÀÖ´Â °Í °°½À´Ï´Ù. ÃÖ±Ù¿¡´Â »è°¨ »ç·Ê°¡ µå¹´´Ï´Ù.


[References]

1) ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª - 2013, 2014, 2015, 2016, 2017

2) [2017-6-10. ¸ÅÀÏ°æÁ¦] ¹é¾ÈÀÇ Àü¶óµµ ³²ÀÚ ÀοäÇÑ

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.